957例胰腺导管腺癌切除术后早期复发的定义与预测
该研究纳入2000至2013年间接受胰腺切除术的957例胰腺导管腺癌患者,排除新辅助治疗和随访不完整者,采用最小P值法确定区分早期与晚期复发的最佳无复发生存截点为12个月(P<0.001),并比较两组临床病理危险因素。
要点
- 无复发生存12个月是区分早期与晚期复发的最佳截点。
- 早期复发者复发后1年和2年生存率分别为20%和6%。
- 术前CA19-9>210 U/mL和术后CA19-9>37 U/mL与早期复发相关。
核心结论
- 基于后续预后,无复发生存间期12个月是区分早期与晚期复发的最佳阈值。
研究设计与样本
- 回顾性队列研究,纳入2000至2013年间接受胰腺切除术的957例胰腺导管腺癌患者,排除新辅助治疗和随访不完整者。
主要发现
- 957例患者中204例(21.3%)末次随访时无复发;早期复发组388例(51.5%),晚期复发组365例(48.5%)。
- 早期复发组复发后1年和2年生存率分别为20%和6%,晚期复发组分别为45%和22%(均P<0.001)。
- 术前早期复发危险因素包括Charlson年龄共病指数≥4(OR 1.65)、CT肿瘤大小>3.0 cm(OR 1.53)和CA19-9>210 U/mL(OR 2.30)。
- 术后早期复发危险因素包括肿瘤分化差(OR 1.66)、微观淋巴血管侵犯(OR 1.70)、淋巴结比率>0.2(OR 2.49)和CA19-9>37 U/mL(OR 3.38)。
- 辅助化疗(OR 0.28)和放化疗(OR 0.29)与降低早期复发可能性相关。
临床怎么用
- 可将无复发生存12个月作为定义早期复发的参考截点,用于临床分层。
- 术前CA19-9>210 U/mL、CT肿瘤>3.0 cm和Charlson年龄共病指数≥4提示早期复发风险较高。
- 术后病理提示分化差、淋巴血管侵犯、淋巴结比率>0.2或CA19-9>37 U/mL时需警惕早期复发。
- 辅助化疗或放化疗与降低早期复发风险相关,应作为综合治疗组成部分。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: To establish an evidence-based cut-off to differentiate between early and late recurrence and to compare clinicopathologic risk factors between the two groups. SUMMARY BACKGROUND DATA: A clear definition of "early recurrence" after pancreatic ductal adenocarcinoma resection is currently lacking. METHODS: Patients undergoing pancreatectomy for pancreatic ductal adenocarcinoma between 2000 and 2013 were included. Exclusion criteria were neoadjuvant therapy and incomplete follow-up. A minimum P-value approach was used to evaluate the optimal cut-off value of recurrence-free survival to divide the patients into early and late recurrence cohorts based on subsequent prognosis. Potential risk factors for early recurrence were assessed with logistic regression models. RESULTS: Of 957 included patients, 204 (21.3%) were recurrence-free at last follow-up. The optimal length of recurrence-free survival to distinguish between early (n = 388, 51.5%) and late recurrence (n = 365, 48.5%) was 12 months (P < 0.001). Patients with early recurrence had 1-, and 2-year post-recurrence survival rates of 20 and 6% compared with 45 and 22% for the late recurrence group (both P < 0.001). Preoperative risk factors for early recurrence included a Charlson age-comorbidity index ≥4 (OR 1.65), tumor size > 3.0 cm on computed tomography (OR 1.53) and CA 19-9 > 210 U/mL (OR 2.30). Postoperative risk factors consisted of poor tumor differentiation grade (OR 1.66), microscopic lymphovascular invasion (OR 1.70), a lymph node ratio > 0.2 (OR 2.49), and CA 19-9 > 37 U/mL (OR 3.38). Adjuvant chemotherapy (OR 0.28) and chemoradiotherapy (OR 0.29) were associated with a reduced likelihood of early recurrence. CONCLUSION: A recurrence-free interval of 12 months is the optimal threshold for differentiating between early and late recurrence, based on subsequent prognosis.
引用
- Groot VP, Gemenetzis G, Blair AB, et al. Defining and Predicting Early Recurrence in 957 Patients With Resected Pancreatic Ductal Adenocarcinoma. Ann Surg. 2019. PMID: 31082915. doi:10.1097/SLA.0000000000002734
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。